Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-86 is an inhibitor targeting the methyltransferases nsp14 and nsp16 of SARS-CoV-2. This compound, a derivative of Andrographolide, demonstrates significant antiviral activity with low toxicity, evidenced by a predicted LD50 of 700 mg/kg. It serves as a valuable research tool for studying SARS-CoV-2 replication and may contribute to therapeutic strategies against COVID-19. -
SARS-CoV-2 Main Protease Inhibitor
X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro), displaying an affinity with a Kd value of 0.057 μM. This compound effectively disrupts the proteolytic activity of Mpro, crucial for viral replication. X77 is primarily utilized in research applications aimed at understanding SARS-CoV-2 biology and developing antiviral therapeutics. -
SARS-CoV 3CLpro Inhibitor
GRL-0496 is a potent inhibitor of SARS-CoV 3CLpro, functioning through targeting the viral protease essential for replication. It demonstrates significant enzyme inhibition with an IC50 of 30 nM and exhibits antiviral activity with an EC50 of 6.9 μM against SARS-CoV. This compound is valuable for research into antiviral therapies and the development of inhibitors aimed at addressing coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
CCF0058981 is a noncovalent inhibitor targeting the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 68 nM. This compound also demonstrates activity against the SARS-CoV-1 3CLpro, exhibiting an IC50 of 19 nM. CCF0058981 shows promising antiviral efficacy and is a valuable tool for research applications focused on COVID-19 and coronavirus protease inhibition. -
SARS-CoV-2 Mpro Inhibitor
TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating significant efficacy in preventing viral replication. This compound is effective in VeroE6 cells, making it a valuable tool for research on COVID-19 pathogenesis and therapeutics. Its role in protease inhibition provides insight into potential antiviral strategies against SARS-CoV-2. -
SARS-CoV-2 inhibitor
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor that functions by inhibiting the SKP2 protein and stabilizing BECN1. With an EC50 value of 1 μM, this compound demonstrates significant antiviral activity against SARS-CoV-2. It is suitable for research applications focusing on viral pathogenesis and the development of therapeutic strategies targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
CDD-1845 is a potent non-covalent, non-peptide inhibitor of SARS-CoV-2 main protease (Mpro) with a Ki of 3 nM. This compound effectively inhibits various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1845 is intended for research applications focused on SARS-CoV-2 protease inhibition and therapeutic development against COVID-19. -
SARS-CoV-2 Inhibitor
Kobophenol A is an oligomeric stilbene that acts as a SARS-CoV-2 inhibitor by hindering the interaction between the ACE2 receptor and the S1-RBD, exhibiting an IC50 value of 1.81 μM. This compound effectively blocks viral infection in cellular models, with an EC50 of 71.6 μM. Additionally, Kobophenol A demonstrates inhibitory activity against partially purified rat brain protein kinase C (PKC), with an IC50 of 52 µM, making it a valuable tool for studies on viral pathogenesis and enzyme regulation. -
SARS-CoV-2 Inhibitor
PAV-104 is an identified inhibitor of SARS-CoV-2, targeting the nucleocapsid (N) protein. By disrupting the oligomerization of the nucleocapsid, PAV-104 effectively interferes with viral particle assembly, thereby impeding replication at a multiplicity of infection (MOI) of 0.01. This compound is a valuable tool for research into antiviral strategies and the mechanistic understanding of SARS-CoV-2 propagation. -
SARS-CoV-2 Inhibitor
MAT-POS-e194df51-1 is an orally active non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 37 nM. This compound exhibits significant cytotoxicity, demonstrated by EC50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells. MAT-POS-e194df51-1 can be utilized in research focusing on antiviral drug development and the pathway exploration of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Main Protease Inhibitor
(Rac)-X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro). It demonstrates strong binding affinity with a Kd value of 0.057 μM, making it valuable for research into antiviral strategies against SARS-CoV-2. This compound is useful for studying protease inhibition mechanisms and developing therapeutic interventions targeting viral replication. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-6 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 73 nM. This compound is critical for research focused on developing antiviral therapeutics against SARS-CoV-2 by targeting its main protease, which is essential for viral replication. Its efficacy makes it suitable for studies aimed at understanding the enzymatic mechanisms of the virus and the development of potential treatment strategies. -
SARS-CoV-2 3CL Protease Inhibitor
MK-7845 is a reversible covalent inhibitor targeting the 3CL protease of SARS-CoV-2, exhibiting an IC50 of 8.7 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the research of COVID-19 therapeutics. Its specificity for the 3CL protease supports investigations into the inhibition of viral replication and pathogenesis, facilitating the development of effective antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-14 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.39 μM. This compound is a niclosamide analogue, demonstrating enhanced stability in human plasma and liver S9 enzyme assays compared to niclosamide. Due to these properties, SARS-CoV-2-IN-14 may offer improved bioavailability and prolonged half-life when administered orally, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
GRL-1720 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 value of 15 µM. This compound exhibits significant anti-SARS-CoV-2 activity, making it a valuable tool for research related to coronavirus infection and therapeutics targeting viral replication. Its efficacy in inhibiting Mpro highlights its potential use in the development of antiviral strategies against SARS-CoV-2. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV-1 Protease Inhibitor
Lasinavir (CGP 61755) is a selective inhibitor of HIV-1 protease, exhibiting an IC50 value of 1 nM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for studying HIV-1 infection and pathogenesis. Lasinavir is applicable in research focused on antiretroviral therapies and the mechanism of protease inhibition in viral replication. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
Parasite Inhibitor
Betulonic acid, a naturally occurring triterpene, primarily targets parasite inhibition. It demonstrates significant antiparasitic activity along with anti-tumor and anti-inflammatory properties. Research applications include studies on its efficacy against various parasites, as well as exploration in cancer and inflammatory disease models. -
HSV Replication Inhibitor
Tromantadine hydrochloride is an antiviral agent that inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). As a derivative of Amantadine, it demonstrates significant antiherpetic activity and is primarily utilized in research applications focused on HSV pathogenesis and therapy development. This compound serves as a valuable tool in the study of viral infections and potential antiviral treatments. -
HSV Inhibitor
Isoborneol, a monoterpenoid alcohol, primarily targets herpes simplex virus type 1 (HSV-1) as a potent inhibitor. Exhibiting both antioxidant and antiviral properties, Isoborneol is utilized in research to explore its efficacy against viral infections. Its presence in the essential oils of various medicinal plants highlights its potential therapeutic applications in virology and pharmacology. -
HSV-1 Inhibitor
Soyasapogenol C is an oleanane-type triterpenoid that demonstrates significant antiviral activity against herpes simplex virus type 1 (HSV-1). With an IC50 value of 18.9 μM, it effectively inhibits viral replication, making it a valuable compound for research in virology and therapeutic development against HSV-1 infections. Its unique mechanism of action and biological potency position Soyasapogenol C as a candidate for further exploration in antiviral studies. -
HSV-1 Inhibitor
5-Nitrobarbituric acid functions as an inhibitor of herpes simplex virus type-1 (HSV-1), exhibiting an IC50 of 1.7 μM. This compound has demonstrated potential in virology research, particularly in studies aiming to understand and combat HSV-1 infections. Its utility in antiviral drug development positions it as a valuable tool for researchers exploring therapeutic strategies against herpes simplex viruses. -
HSV Inhibitor
1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil is a nucleoside analogue that specifically targets herpes simplex virus (HSV). This compound exhibits potent antiviral activity by inhibiting viral replication. It is utilized in research focused on developing therapeutic strategies for HSV infections and studying viral pathogenesis. -
HSV Polymerases Inhibitor
PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research. -
HSV-1 Inhibitor
Leachianone G is an antiviral flavonoid derived from the root bark of Morus alba L., targeting herpes simplex virus type 1 (HSV-1). It exhibits significant antiviral activity, demonstrating an IC50 value of 1.6 μg/mL. This compound may be utilized in research focused on antiviral therapeutics and the mechanisms of HSV-1 infection. -
HSV Inhibitor
HN0037 is a selective helicase-primase inhibitor targeting the herpes simplex virus (HSV). By interfering with the viral helicase-primase complex composed of UL5, UL52, and UL8 proteins, HN0037 effectively inhibits HSV replication. Its mechanism of action makes it a valuable research tool for studying antiviral therapies and HSV pathogenesis. -
HSV Inhibitor
5'-Ethynyl-2'-deoxycytidine is a potent inhibitor of herpes simplex virus (HSV), effectively reducing the cytopathic effects of HSV-1 in primary rabbit kidney cells with a minimum inhibitory concentration (MIC) of 0.2 μg/mL. Additionally, this compound demonstrates anti-proliferative activity against leukemia L1210 cells, exhibiting an IC50 value of 64.5 μg/mL. It serves as a valuable tool for researchers investigating viral infections and cancer biology. -
HSV Inhibitor
Stearyl gallate, an alkyl gallate with an 18-carbon long alkyl chain, primarily functions as an antiviral agent against herpes simplex virus type 1 (HSV-1). This compound exhibits notable antioxidant properties, making it a useful tool in research focused on viral inhibition and oxidative stress. Its multifaceted biological activity positions stearyl gallate as a candidate for further investigation in the development of therapeutic agents targeting viral infections. -
HSV Inhibitor
Tromantadine is an effective inhibitor of herpes simplex virus (HSV) replication, specifically targeting HSV-1 and HSV-2. As a derivative of Amantadine, it demonstrates significant antiherpetic activity, making it suitable for research applications focused on viral infection mechanisms and potential therapeutic interventions. -
HSV Inhibitor
Ganoderone A is a triterpene compound known for its inhibitory activity against herpes simplex virus (HSV). With an IC50 value of 0.3 µg/mL, it demonstrates significant antiviral properties. Ganoderone A shows promise for applications in the treatment of viral infections and may also have relevance in cancer research. -
HSV Inhibitor
11-Deoxymogroside IIE is a cucurbitane glycoside derived from the fruits of Siraitia grosvenorii, primarily targeting viral inhibition. It exhibits notable inhibitory effects against the activation of the Epstein-Barr virus (EBV-EA) when induced by TPA. Additionally, it demonstrates a weak inhibitory effect on the nitric oxide donor, NOR1. This compound serves as a valuable tool for research focused on viral infections and their mechanisms. -
HSV-1/2 Inhibitor
Peniterphenyl A is a potent inhibitor of herpes simplex virus types 1 and 2 (HSV-1/2) through direct interaction with the viral envelope glycoprotein D. It effectively blocks the entry of the virus into host cells, thereby preventing infection by disrupting virus adsorption and membrane fusion processes. This natural product, derived from a deep-sea Penicillium species, represents a promising lead compound for further research and development in the field of antiviral therapeutics against HSV-1 and HSV-2. -
HSV-1 Inhibitor
WAY-150138 is a selective inhibitor of herpes simplex virus type 1 (HSV-1), functioning by obstructing the incorporation of DNA-packaging proteins into viral capsids during assembly. This compound demonstrates potent antiviral activity against HSV-1 and may serve as a valuable tool for studying the mechanisms of viral replication and the development of antiviral therapies. Its application in research on HSV-1 will aid in understanding the virus's life cycle and identifying potential therapeutic interventions. -
HSV-1/2 Inhibitor
HSV-1/HSV-2-IN-2 is an inhibitor of both HSV-1 and HSV-2, displaying effective antiviral activity with EC50 values of 6.8 µM and 8.9 µM, respectively. This compound is also active against Varicella Zoster Virus (VV), with an EC50 value of 8.9 µM. HSV-1/HSV-2-IN-2 is suitable for research applications focused on understanding herpesvirus biology and potential therapeutic strategies. -
HSV-1/HSV-2 Inhibitor
HSV-1/HSV-2-IN-1 is a potent inhibitor targeting both HSV-1 and HSV-2 with EC50 values of 7.6 µM for HSV-1 (KOS) and 7.6 µM for HSV-2 (G). It also demonstrates activity against HSV-1 TK- KOS ACVr and vaccinia virus, showing EC50 values of 4 µM and 12 µM, respectively, in human embryonic lung fibroblast cell cultures. This compound is suitable for research focused on antiviral therapies and the mechanisms of herpesvirus infection. -
HSV Inhibitor
Karalicin is an antiviral agent that functions as an inhibitor of herpes simplex virus (HSV-1 and HSV-2), vaccinia virus, and poliovirus type I. It exhibits potent inhibitory activity, with IC50 values of 0.004 μg/mL for HSV-1, 0.008 μg/mL for HSV-2, and 0.016 μg/mL for both vaccinia virus and poliovirus type I. This compound is valuable for research into antiviral therapies and the mechanistic study of viral infections. -
HSV-1/2 Inhibitor
5-(4-Carboxyphenyl)-10,15,20-triphenylporphyrin is a porphyrin compound that targets herpes simplex viruses 1 and 2 (HSV-1/2). It demonstrates potent virucidal activity, achieving inhibition rates of 85% against HSV-1 and 60% against HSV-2, with a maximum noncytotoxic concentration of 5 μg/mL on Vero cells. This compound serves as a valuable tool for studying antiviral mechanisms and can facilitate the synthesis of derivatives with enhanced antiviral efficacy. -
HSV-1 Inhibitor
17,17-Ethylendioxyandrost-5-en-3β-ol acts as an inhibitor of herpes simplex virus type 1 (HSV-1), displaying an EC50 value of 629 μM. This compound is relevant for research focused on viral infections and can be utilized to explore mechanisms of viral replication and potential therapeutic strategies against HSV-1. -
HSV-2 Inhibitor
SCH-43478 is a non-nucleoside antiviral agent that targets herpes simplex virus type 2 (HSV-2). It exhibits potent and selective activity with an IC50 of 1.8 μg/mL in Vero cells. Additionally, SCH-43478 shows significant efficacy in preclinical models of HSV infection, specifically in the guinea pig genital model, making it a valuable tool for research on antiviral therapies. -
HSV-1/HSV-2 Inhibitor
HSV-1/HSV-2-IN-3 is a potent inhibitor of the herpes simplex virus (HSV) helicase-primase complex, effectively disrupting the DNA unwinding and primer synthesis necessary for viral genome replication. It demonstrates an EC50 of 7.0 nM against HSV-2 in gD-immunofluorescence assays, and 1.1 nM in qPCR replication assays, highlighting its potent antiviral activity. Additionally, HSV-1/HSV-2-IN-3 exhibits high selectivity for viral targets, with an IC50 of approximately 2.9 µM for human carbonic anhydrase II, making it a valuable tool for anti-HSV research applications. -
HSV Inhibitor
(S)-HN0037 is a selective helicase-primase inhibitor that effectively targets the viral helicase-primase complex, thereby inhibiting herpes simplex virus (HSV) replication. Its oral bioactivity makes it a valuable tool for studying HSV pathology and developing antiviral therapies. Researchers can utilize (S)-HN0037 in various experimental models to investigate mechanisms of viral replication and explore potential therapeutic interventions against HSV infections. -
HSV Inhibitor
C-AFG is a novel herpes simplex virus (HSV) inhibitor that demonstrates potent activity against both HSV-1 and HSV-2. This compound exhibits high selectivity, making it a valuable tool for research on viral infections and the mechanisms of antiviral action. C-AFG is suitable for studies focusing on therapeutic strategies against herpesvirus-related diseases. -
HSV Inhibitor
HSV-1-IN-3 is a potent inhibitor of herpes simplex virus (HSV) with demonstrated antiviral activity against both Acyclovir-sensitive and -resistant HSV strains. This compound has potential applications in virology research, particularly in studies focused on understanding and developing treatments for HSV infections. Its effectiveness against resistant strains makes it a valuable tool in the search for new antiviral therapies. -
HSV-1 Inhibitor
Woodorien is a potent inhibitor of herpes simplex virus type 1 (HSV-1), demonstrating strong antiviral activity. Isolated from the plant Woodwardia orientalis, Woodorien functions as a glucoside that impacts viral replication. This compound serves as a valuable tool for studying HSV-1 infection mechanisms and the development of antiviral therapies. -
Endonuclease Inhibitor
AV5116 is a cap-dependent endonuclease inhibitor that specifically targets the active site of the cap-dependent endonuclease (CEN) within the N-terminal domain of polymerase acidic. This compound demonstrates potent inhibitory activity against various influenza viruses, including types A, B, and C. AV5116 is valuable for research investigating influenza virus infections and the mechanisms of antiviral action. -
Influenza Virus Inhibitor
β-Cyclodextrin is a cyclic polysaccharide that targets influenza virus inhibition, specifically effective against the H1N1 strain. Its primary mechanism involves enhancing the solubility of various compounds, making it a valuable tool in virology research. Additionally, β-Cyclodextrin demonstrates significant antiviral activity, providing potential therapeutic applications in the treatment of influenza. -
Neuraminidase Inhibitor
2,3-Dehydro-2-deoxy-N-acetylneuraminic acid is a potent inhibitor of neuraminidase enzymes, functioning primarily through competitive inhibition. This compound demonstrates significant inhibitory effects on human neuraminidase isoforms NEU1, NEU2, NEU3, and NEU4, with IC50 values of 143, 43, 61, and 74 μM, respectively. Its inhibitory activity positions it as a valuable tool for researching anti-influenza virus mechanisms and for studying sialidase-related biological processes. -
Influenza Viru Inhibitor
Desaminotyrosine is an influenza virus inhibitor that enhances type I interferon signaling. This microbial metabolite plays a crucial role in the immune response against influenza, offering protective effects by promoting antiviral activity. Its mechanism of action makes it valuable for research into antiviral therapies and immune modulation strategies. -
Influenza Viru Inhibitor
L-Norleucine, a derivative of leucine, primarily functions as an antiviral agent by inhibiting protein synthesis, particularly in the context of influenza virus infections. Its activity interferes with viral replication, making it a valuable reagent for research applications focused on viral biology and therapeutic interventions against influenza. L-Norleucine can be utilized in studies exploring mechanisms of protein synthesis modulation and the development of antiviral strategies.
